Related Experiment Video

Updated: Nov 1, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.1K

Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated

Eugene E Wright1, Matthew S D Kerr2, Ignacio J Reyes2

  • 1Charlotte Area Health Education Center, Charlotte, NC.

Diabetes Spectrum : a Publication of the American Diabetes Association
|June 21, 2021
PubMed
Abstract

Insights

Flash continuous glucose monitoring (CGM) significantly reduced A1C levels in type 2 diabetes patients on nonintensive therapy. This technology offers a valuable tool for improving glycemic control in a wider patient population.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Diabetes Management

Background:

  • Suboptimal glycemic control affects many individuals with type 2 diabetes.
  • Flash continuous glucose monitoring (CGM) has shown A1C reductions in intensively treated patients.
  • Its benefit in nonintensively treated type 2 diabetes patients remains less studied.

Purpose of the Study:

  • To evaluate the glycemic impact of flash CGM in type 2 diabetes patients on nonintensive therapy.
  • To assess A1C changes after flash CGM prescription in this population.

Main Methods:

  • Retrospective observational study using the IBM Explorys database.
  • Included 1,034 adults with type 2 diabetes, baseline A1C ≥8%, on basal insulin or noninsulin therapy, and new to CGM.
  • Patients served as their own controls, analyzing A1C before and after flash CGM (FreeStyle Libre) initiation.

Main Results:

  • A significant A1C reduction from 10.1% to 8.6% (Δ -1.5%) was observed in the full cohort (P <0.001).
  • Greatest A1C reductions occurred in those with baseline A1C ≥12.0% (Δ -3.7%, P <0.001).
  • Significant A1C reductions were noted in both basal insulin (-1.1%) and noninsulin (-1.6%) treatment groups (P <0.001).

Conclusions:

  • Flash CGM prescription is linked to significant A1C reductions in type 2 diabetes patients on nonintensive regimens.
  • Findings support broader access to flash CGM for individuals with type 2 diabetes.
  • This technology can improve glycemic control in diverse treatment settings.

More Related Videos

Simple Continuous Glucose Monitoring in Freely Moving Mice03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

6.6K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.5K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
648
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.6K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
313
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
378
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
338